Search

everythinglearnresearchcommunity

for

Search:↓

User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.

A user is considering dutasteride mesotherapy versus oral finasteride for hair loss, with concerns about side effects. Other users share experiences with both treatments, suggesting oral finasteride as more effective and cost-efficient, while also discussing the use of minoxidil, alfatradiol, and potential side effects like gynecomastia.

The user's experience using Minoxidil to treat hair loss, with discussion of Finasteride and RU58841 as additional treatments. Additional advice is provided on ketozolin shampoo use and microdosing finasteride.

A user who has started to go bald and decided to try wearing a hair piece, discussing the experience of doing so and sharing tips for maintenance. The conversation includes discussion about confidence in relation to wearing a wig or hair piece, as well as advice on getting it cut and attached professionally.

User tired of receding hairline and maintenance, shaved head. Others compliment shaved look and beard genetics.

Minoxidil and finasteride are the main treatments for hair loss, with Breezula and hair cloning being explored. No definitive cure is available yet.

The post and conversation are about microneedling as a treatment for alopecia. It provides a comprehensive review of scientific literature on the technique and its application.

A user's experience with dealing with hair loss, and the advice that was shared by other users to cope with it. Suggested treatments included shaving their head, using medications such as finasteride, minoxidil, and dutasteride, as well as dermarolling.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

A user traveled to Turkey for a 5000-graft FUE hair transplant at ASMED Clinic with Dr. Koray Erdogan. They used finasteride before and after the surgery and shared detailed experiences, costs, and recovery tips.

Oral Minoxidil (Loniten) effectively promotes hair regrowth, especially on the crown and temples, with minimal side effects like extra body hair. The user found it more convenient and effective than topical Minoxidil and had negative experiences with Finasteride and Dutasteride.

The user is struggling with hair loss and has tried treatments like finasteride, minoxidil, and hair systems, each with drawbacks. They are considering retrying finasteride before a hair transplant and are advised to seek therapy for mental health support.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

A 36-year-old is concerned about early hairline recession despite no family history of hair loss. They are considering treatments like finasteride, minoxidil, and ketoconazole shampoo but are worried about potential side effects and are seeking natural alternatives.

A 23-year-old feels devastated by hair loss despite using Minoxidil and finasteride since age 18, and is advised to embrace baldness, improve physical fitness, and consider hair systems. The conversation emphasizes self-acceptance, confidence, and exploring new interests to improve mental well-being.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

A user ordered Alpha Plus from Anagenica, expecting it to contain specific percentages of Fin, Estradiol, Minoxidil, and CB0301. However, the received product's label showed different percentages, including a surprising 25% CB, leading the user to question its safety and accuracy.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.